Our Mission at Hyperion Therapeutics
Revolutionize the standard of care to combat our world's leading causes of blindness:
👁 Age-related Macular Degeneration (AMD)
👁 Diabetic Retinopathy (DR)
👁 Retinitis Pigmentosa (RP)
👁 and more...
An urgent, unmet medical need
Prioritizing new medications to effectively preserve eyesight in the most common age-related and inherited retinal diseases, impacting over 420 million patients worldwide.
A new class of therapeutics in SREDs
Pioneering "Stress Resilience-Enhancing Drugs" (SREDs) – a novel, multi-targeted therapeutic strategy, for the treatment of neurodegenerative conditions, to restore homeostasis among multiple cell types implicated in disease.